Bexorg has received up to $28.3 million from ARPA-H to extend its BrainEx platform, which perfuses intact donated human brains, from 24 hours of viable study time to as long as two weeks across a 36-month, three-phase project. The longer window would allow repeated dosing, sustained drug exposure and longitudinal molecular measurement within intact human neural and vascular tissue. For neurodegenerative disease research, where candidate therapies routinely fail between preclinical promise and clinical trials, the platform offers human-specific pharmacological data before first-in-human dosing.
Key Points
- ARPA-H funds extension of human brain perfusion to two weeks
- Longer window captures repeated dosing and delayed drug effects
- Two-week viability and clinical correlation remain unproven goals
Longevity Analysis
Brain aging research has been constrained by models that cannot reproduce human neurovascular architecture, and much of the attrition in Alzheimer's drug development traces to signals read correctly in animals but mislabeled in humans. Sustaining circulation through intact donated tissue for days rather than hours allows researchers to observe how neural cells, vasculature and clearance pathways actually respond to sustained exposure, the timescale on which most degenerative processes and therapeutic effects unfold. The gain here is interpretive precision, with the caveat that neither two-week viability nor agreement with clinical outcomes has yet been demonstrated.
Original published by Longevity.Technology, by Kyle Umipig.